Andrew J. Ullmann

Active 2000–2022

69
Papers
22,711
Citations
67
h-index
69
i10-index

Citations

Citations per year for Andrew J. Ullmann1991: 1 citations2001: 1 citations2002: 2 citations2003: 3 citations2004: 7 citations2005: 20 citations2006: 17 citations2007: 85 citations2008: 113 citations2009: 92 citations2010: 122 citations2011: 104 citations2012: 99 citations2013: 115 citations2014: 162 citations2015: 147 citations2016: 221 citations2017: 191 citations2018: 214 citations2019: 786 citations2020: 734 citations2021: 771 citations2022: 492 citations2023: 395 citations2024: 632 citations2025: 272 citations2026: 2 citations1992–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,361 citing papers, 17% of this breakdownGermany: 571 citing papers, 7.2% of this breakdownFrance: 484 citing papers, 6.1% of this breakdownUnited Kingdom: 480 citing papers, 6% of this breakdownItaly: 382 citing papers, 4.8% of this breakdownSpain: 378 citing papers, 4.7% of this breakdownNetherlands: 308 citing papers, 3.9% of this breakdownChina: 304 citing papers, 3.8% of this breakdownIndia: 262 citing papers, 3.3% of this breakdownAustralia: 259 citing papers, 3.2% of this breakdownAustria: 236 citing papers, 3% of this breakdownSwitzerland: 234 citing papers, 2.9% of this breakdown
0%17%Other 34.1%

Fields

  • Medicine86.7%
  • Biochemistry, Genetics and Molecular Biology5.5%
  • Immunology and Microbiology3.5%
  • Engineering0.6%
  • Computer Science0.6%
  • Agricultural and Biological Sciences0.5%
  • Other2.6%

Topics

  • Antifungal resistance and susceptibility20.4%
  • Fungal Infections and Studies13.9%
  • Cytomegalovirus and herpesvirus research4.1%
  • Pneumocystis jirovecii pneumonia detection and treatment3%
  • Neutropenia and Cancer Infections2.8%
  • Herpesvirus Infections and Treatments2.2%
  • Other53.6%

Coauthors

All papers

Open in search
  1. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Claus Peter Heußel, C Kibbler, Н Н Климко, Bart Jan Kullberg, Christoph Lange, Thomas Lehrnbecher, Jürgen Löffler, Olivier Lortholary, Johan Maertens, Oscar Marchetti, Jacques F. Meis, Livio Pagano, Patricia Ribaud, Malcolm Richardson, Emmanuel Roilides, Markus Ruhnke, Maurizio Sanguinetti, Donald C. Sheppard, János Sinkó, Anna Skiada, Maria J. G. T. Vehreschild, Claudio Viscoli, Oliver A. Cornely - Clinical Microbiology and Infection 2018 cited by 1,518

  2. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jesús Guinea, Claus Peter Heußel, Ashraf S. Ibrahim, Souha S. Kanj, Н Н Климко, Michaela Lackner, Frédéric Lamoth, Fanny Lanternier, Cornelia Lass-Floerl, Dong‐Gun Lee, Thomas Lehrnbecher, B. Lmimouni, Mihai Mareș, Georg Maschmeyer, Jacques F. Meis, Joseph Meletiadis, C. Orla Morrissey, Márcio Nucci, Rita Oladele, Livio Pagano, Alessandro C. Pasqualotto, Atul Patel, Zdeněk Ráčil, Malcolm Richardson, Emmanuel Roilides, Markus Ruhnke, Seyedmojtaba Seyedmousavi, Neeraj Sidharthan, Nina Singh, János Sinkó, Anna Skiada, Monica A. Slavin, Rajeev Soman, Brad Spellberg, William J. Steinbach, Ban Hock Tan, Andrew J. Ullmann, Jörg Janne Vehreschild, Maria J. G. T. Vehreschild, Thomas J. Walsh, P. Lewis White, Nathan P. Wiederhold, Theoklis E. Zaoutis, Arunaloke Chakrabarti - The Lancet Infectious Diseases 2019 cited by 1,756

  3. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 1,206

  4. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2015 cited by 972

  5. ESCMID∗ guideline for the diagnosis and treatment of biofilm infections 2014

    Authors: , , , , , , , , , , , , , - Clinical Microbiology and Infection 2015 cited by 784

  6. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Microbiology and Infection 2012 cited by 1,214

  7. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

    Authors: , , , , , , , , - European Respiratory Journal 2015 cited by 1,012

  8. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2007 cited by 1,807

  9. Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany

    Authors: , , , , , , - The Lancet Regional Health - Europe 2022 cited by 87

  10. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Clinical Microbiology and Infection 2012 cited by 362

  11. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2007 cited by 1,336

  12. Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

    Authors: , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2007 cited by 744

  13. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Microbiology and Infection 2012 cited by 395

  14. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shallu Kathuria, Olivier Lortholary, Jacques F. Meis, Andrew J. Ullmann, G. Petrikkos, Cornelia Lass‐Flörl - Clinical Microbiology and Infection 2014 cited by 511

  15. ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew J. Ullmann, Anne van Diepeningen, Paul E. Verweij, G. Petrikkos - Clinical Microbiology and Infection 2014 cited by 858

  16. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet 2007 cited by 689

  17. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 371

  18. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anna Maria Tortorano, Andrew J. Ullmann, Paul E. Verweij, Oliver A. Cornely, Manuel Cuenca‐Estrella - Clinical Microbiology and Infection 2014 cited by 362

  19. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016

    Authors: , , , , , , , , , , , , , - Annals of Hematology 2016 cited by 211

  20. Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

    Authors: , , , , , , , , , , , , , , , , , , , , , - Mycoses 2020 cited by 72

  21. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Microbiology and Infection 2012 cited by 335

  22. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of Hematology 2017 cited by 215

  23. Forty-one recent cases of invasive zygomycosis from a global clinical registry

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Antimicrobial Chemotherapy 2009 cited by 201

  24. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries

    Authors: , , , , , , , , , , , , , , , , , , , , - Haematologica 2013 cited by 122